Deal: The development agreement will facilitate Ginkgo and Microba’s collaboration on projects that develop live biotherapeutics for lupus, psoriatic arthritis and other autoimmune liver diseases – “all with the goal of improving treatment”, Minter said in a statement.

Area: Capital markets

Value: N/A

Key players: The Minter team was led by partner James Hutton, who was supported by corporate specialist Esmond Prowse and a cross-disciplinary MinterEllison team comprising specialists in intellectual property, tax, foreign investment, trade and transaction solutions.

Deal significance: Mr Hutton said: “We’re delighted to support Ginkgo in this transaction to help them work towards their collaboration and great health outcomes for the community.

VIEW ALL

“The pandemic has continued to put a spotlight on the importance of life sciences and biotech for the wellbeing of the global community. Global partnerships like Ginkgo and Microba’s are a great example of how organisations are harnessing this to rapidly develop and improve diagnostics and treatment options.

“This also continues a theme of the growing importance of utilising computer power in life science platform technologies.”